Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CD47/SIRPalpha pathway modulators - Prothya BioSolutions/Byondis

Next Previous
Drug Profile

Research programme: CD47/SIRPalpha pathway modulators - Prothya BioSolutions/Byondis

Alternative Names: CD47 antigen/SIRPalpha protein modulators; CD47-SIRPα modulators

Latest Information Update: 28 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanquin Blood Supply Foundation
  • Developer Byondis; Prothya BioSolutions
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Phagocyte stimulants; SIRPA protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Jul 2021 No recent reports of development identified for research development in Cancer in Netherlands (Parenteral)
  • 16 Apr 2020 Synthon Biopharmaceuticals is now called Byondis
  • 31 Jul 2018 Forty Seven sub-licenses patent pertaining to 5F9 from Synthon Biopharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top